New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
10.3350/cmh.2015.21.2.115
- Author:
Hyun Young WOO
1
;
Jeong HEO
Author Information
1. Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Korea. jheo@pusan.ac.kr
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- Keywords:
Management;
Hepatocellular carcinoma;
Portal vein thrombosis
- MeSH:
Carcinoma, Hepatocellular/complications/*pathology/therapy;
Chemoembolization, Therapeutic;
Combined Modality Therapy;
Humans;
Liver Neoplasms/complications/*pathology/therapy;
Niacinamide/administration & dosage/analogs & derivatives;
Phenylurea Compounds/administration & dosage;
Portal Vein;
Protein Kinase Inhibitors/administration & dosage;
Venous Thrombosis/complications/*pathology
- From:Clinical and Molecular Hepatology
2015;21(2):115-121
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.
